Physician profile
Robert R Greene
NPI 1639193709
$3,158.32
in general payments reported to CMS, 2019-2025
20 companies · $345 in 2025
The $345 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,689 · 2020: $30.40 · 2021: $466 · 2022: $410 · 2023: $167 · 2024: $51.95 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $563.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,090.54 | 2021-2025 | Mazor X System, Advisa Dr Mri Surescan |
| Abiomed | $294.17 | 2019-2023 | Impella |
| Medtronic Vascular, INC. | $257.54 | 2019 | |
| Janssen Pharmaceuticals, INC | $183.56 | 2019 | |
| Astellas Pharma US INC | $174.93 | 2019 | |
| Bardy Diagnostics, INC. | $147.39 | 2021-2022 | |
| Amgen INC. | $145.55 | 2019 | |
| Pfizer INC. | $114.80 | 2019 | |
| Sanofi-Aventis U.S. LLC | $108.24 | 2019 | |
| Vifor Pharma, INC. | $104.88 | 2019 | |
| Akcea Therapeutics, INC. | $91.14 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.85 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.41 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $71.30 | 2019 | |
| Abbott Laboratories | $51.95 | 2024 | Assurity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $50.64 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $39.19 | 2019 | |
| Chiesi USA, INC. | $26.73 | 2019 | |
| Irhythm Technologies, INC. | $18.51 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Greene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.